Fate of Biogen's stock rides on Alzheimer's drug decision
If FDA regulators give Biogen approval to market aducanumab, the stock could surge to as much to $450, according to Wall Street analysts.
More from Michigan Business
DetroitNews Business
US stocks slip as investors weigh economic data, Fed policy
Michigan Business
•
Dec 5, 2022
DetroitNews Business
Sale jumpstarts floating, offshore wind power in US waters
Michigan Business
•
Dec 5, 2022
DetroitNews Business
Stocks open lower on Wall Street, crude oil prices climb
Michigan Business
•
Dec 5, 2022
Michigan Lawyers Weekly
Reformers take 6 of 14 UAW board seats, could win majority
Michigan Business
•
Dec 5, 2022
Michigan Lawyers Weekly
Tolling exception to one-year-back rule readopted
Michigan Business
•
Dec 5, 2022
DetroitNews Business
India signals it will continue to buy oil from Russia
Michigan Business
•
Dec 5, 2022
DetroitNews Business
As Musk is learning, content moderation is a messy job
Michigan Business
•
Dec 5, 2022
DetroitNews Business
Elon Musk says Apple is 'fully' advertising on Twitter again
Michigan Business
•
Dec 4, 2022